Friday, June 12, 2026

Patent directory Β· USPTO A61K / A61P

Browse patents

Browse 30,257 pharma-relevant patents (US A61K/A61P) linked to tracked companies, drugs, and pipeline programs.

Patents indexed 30,257
Companies 1,769
Drugs linked 4,797

Quick answer

NovaPharmaNews indexes 30,257 US pharmaceutical patents from USPTO PatentsView (CPC A61K/A61P), cross-linked to company assignees, drug INN profiles, and pipeline programs. Search by patent number, applicant, title, or CPC code β€” or use facet hubs for expiring patents, assignees, and therapeutic areas.

Patent results

Page 169 of 1,261
  1. US 11759427

    Formation of stable submicron peptide or protein particles by thin film freezing

    The Board of Regents of the University of Texas System Β· Granted Sep 19, 2023 Β· Expires Sep 14, 2043

    granted
  2. US 11761000

    Compositions and their uses directed to huntingtin

    Ionis Pharmaceuticals, Inc. Β· Granted Sep 19, 2023 Β· Expires Sep 14, 2043

    granted
  3. CN 116783219

    T cell recruitment polypeptides based on TCR alpha/beta reactivity

    ABLYNX NV Β· Granted Sep 19, 2023 Β· Expires Sep 14, 2043

    granted
  4. US 11760803

    Methods of treating gastrointestinal immune-related adverse events in immune oncology treatments

    Takeda Pharmaceutical Company Limited Β· Granted Sep 19, 2023 Β· Expires Sep 14, 2043

    granted
  5. US 11759525

    Muscle targeting complexes and uses thereof for treating facioscapulohumeral muscular dystrophy

    Dyne Therapeutics, Inc. Β· Granted Sep 19, 2023 Β· Expires Sep 14, 2043

    granted
  6. US 11760714

    Methods of making bempedoic acid and compositions of the same

    Esperion Therapeutics, Inc. Β· Granted Sep 19, 2023 Β· Expires Sep 14, 2043

    granted
  7. US 11760740

    Highly purified pharmaceutical grade tasimelteon

    VANDA PHARMACEUTICALS INC. Β· Granted Sep 19, 2023 Β· Expires Sep 14, 2043

    granted
  8. US 11760775

    Steroids and protein-conjugates thereof

    REGENERON PHARMACEUTICALS, INC. Β· Granted Sep 19, 2023 Β· Expires Sep 14, 2043

    granted
  9. US 11761006

    Use of MIR101 or MIR128 in the treatment of seizure disorders

    OVID THERAPEUTICS INC. Β· Granted Sep 19, 2023 Β· Expires Sep 14, 2043

    granted
  10. US 11760761

    Methods and compositions for targeting PD-L1

    Aligos Therapeutics, Inc. Β· Granted Sep 19, 2023 Β· Expires Sep 14, 2043

    granted
  11. US 11759526

    Method and molecules

    The Regents of the University of California Β· Granted Sep 19, 2023 Β· Expires Sep 14, 2043

    granted
  12. US 11759531

    Gene therapy vectors for treating heart disease

    Tenaya Therapeutics, Inc. Β· Granted Sep 19, 2023 Β· Expires Sep 14, 2043

    granted
  13. US 11760755

    Hepatitis B antiviral agents

    Enanta Pharmaceuticals, Inc. Β· Granted Sep 19, 2023 Β· Expires Sep 14, 2043

    granted
  14. US 11760764

    Methods and compositions for targeting PD-L1

    Aligos Therapeutics, Inc. Β· Granted Sep 19, 2023 Β· Expires Sep 14, 2043

    granted
  15. US 11759515

    Compositions and methods for inducing immune responses

    ARCTURUS THERAPEUTICS, INC. Β· Granted Sep 19, 2023 Β· Expires Sep 14, 2043

    granted
  16. US 11760790

    Neutralizing antibodies to HIV-1 Env and their use

    The United States of America, as represented by the Secretary, Department of Health and Human Services Β· Granted Sep 19, 2023 Β· Expires Sep 14, 2043

    granted
  17. US 11760980

    Induced pluripotent stem cells (IPSCS) and applications thereof

    China Medical University Β· Granted Sep 19, 2023 Β· Expires Sep 14, 2043

    granted
  18. US 11759506

    AADC polynucleotides for the treatment of Parkinson's disease

    VOYAGER THERAPEUTICS, INC. Β· Granted Sep 19, 2023 Β· Expires Sep 14, 2043

    granted
  19. US 11760987

    Compositions and methods for the treatment or prevention of heart failure

    The Regents of the University of California Β· Granted Sep 19, 2023 Β· Expires Sep 14, 2043

    granted
  20. US 11760795

    Monoclonal antibodies to growth and differentiation factor 15 (GDF-15), and uses thereof for treating cancer cachexia and cancer

    Julius-Maximilians-Universitat Wurzburg Β· Granted Sep 19, 2023 Β· Expires Sep 14, 2043

    granted
  21. US 11760794

    Neutralizing antibodies to plasmodium falciparum circumsporozoite protein and their use

    The United States of America, as represented by the Secretary, Department of Health and Human Services Β· Granted Sep 19, 2023 Β· Expires Sep 14, 2043

    granted
  22. US 11760789

    Broadly neutralizing antibodies against HIV

    United States Government as represented by the Department of Veterans Affairs Β· Granted Sep 19, 2023 Β· Expires Sep 14, 2043

    granted
  23. US 11760858

    Dendritic macroporous hydrogels prepared by crystal templating

    The Board of Regents of the University of Texas System Β· Granted Sep 19, 2023 Β· Expires Sep 14, 2043

    granted
  24. US 11759522

    Pharmaceutical compositions comprising meloxicam

    AXSOME THERAPEUTICS, INC. Β· Granted Sep 19, 2023 Β· Expires Sep 14, 2043

    granted

Frequently asked questions

What patents are included in this directory?

We index 30,257 published US pharma-relevant patents filtered to CPC classes A61K and A61P, with assignee links to our company directory where a match exists.

How do I search for a patent?

Use the search box to match patent number, title, applicant name, or CPC classification (e.g. A61K). For cross-entity queries spanning news and drugs, use the global search.

How is this different from the patent intelligence dashboard?

The dashboard at /patents highlights expirations, recent grants, and assignee rankings. Browse is the full paginated directory with search β€” best for looking up a specific filing or applicant portfolio slice.